Buchumschlag

Timely Follow‐Up After a First Diagnosis of Cirrhosis is Associated With Reduced Mortality but No Impact on Rehospitalisations: A Population‐Based Cohort of 8852 Patients

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Max S. Schechter, Linnea Widman, Axel Wester, Ying Shang, Per Stål, Brett Fortune, Hannes Hagström
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Timely Follow‐Up in Cirrhosis: How Does It Work?
von: Nina Kimer, et al.
Veröffentlicht: (2024)

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention
von: Mo‐Yao Tan, et al.
Veröffentlicht: (2024)

Editorial: MetALD and Risk of Gastrointestinal Cancer—What Can We Learn From Japan?
von: Hannes Hagström, et al.
Veröffentlicht: (2025)

Spontaneous Bacterial Peritonitis Is Associated With High Mortality, Which Interacts With Antibiotic Prophylaxis in a National Cirrhosis Cohort
von: Scott Silvey, et al.
Veröffentlicht: (2025)

Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
von: Bernardo de Faria Moraes, et al.
Veröffentlicht: (2026)

Women's Health Disorders in a Coeliac Disease Population After Diagnosis—A Nationwide Cohort Analysis
von: Rama Nanah, et al.
Veröffentlicht: (2025)

Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
von: Yuki Utakata, et al.
Veröffentlicht: (2026)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
von: Zhanbo Qu
Veröffentlicht: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
von: Yuki Utakata, et al.
Veröffentlicht: (2026)

Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Soroor Owrangi, et al.
Veröffentlicht: (2024)

Patient Plasma‐Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis
von: Supachaya Sriphoosanaphan, et al.
Veröffentlicht: (2025)

Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): A Population‐Based Cohort Study
von: Yee Hui Yeo, et al.
Veröffentlicht: (2025)

Mortality of Acute Kidney Injury in Cirrhosis: A Systematic Review and Meta‐Analysis of Over 5 Million Patients Across Different Clinical Settings
von: Vasileios Lekakis, et al.
Veröffentlicht: (2024)

Late Diagnosis of Chronic Hepatitis B in the United States: A Population‐Based, Retrospective Cohort Study From 2007 to 2021
von: Michael H. Le, et al.
Veröffentlicht: (2025)

Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation
von: David Tornai, et al.
Veröffentlicht: (2025)

Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study
von: Adriana Palom, et al.
Veröffentlicht: (2026)

Barriers to Medical Care Are Frequently Reported by Patients With Cirrhosis
von: William Chai, et al.
Veröffentlicht: (2025)

Treatment‐Free Outcomes Following Surgery for IBD : A Nationwide Cohort Study
von: Adam S. Faye, et al.
Veröffentlicht: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation
von: Thanawin Pramotedham, et al.
Veröffentlicht: (2026)

Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis
von: Deliang Huang, et al.
Veröffentlicht: (2026)

Chronic Use of Proton Pump Inhibitors Is Associated With Reduced 30‐Day Mortality From Acute Pancreatitis
von: Maya Fischman, et al.
Veröffentlicht: (2025)

Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow‐Up Study
von: Christy Riggott, et al.
Veröffentlicht: (2025)

Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid‐Lowering
von: Emily Stephenson, et al.
Veröffentlicht: (2026)

Editorial: Linking Patients With Cirrhosis to Clinical Care—The Hurdles and Way Forward
von: Jimmy Che‐To Lai, et al.
Veröffentlicht: (2026)

Unstable Recompensation: An Intermediate Subtype in Patients With HBV ‐Related Decompensated Cirrhosis
von: Shuai Xia, et al.
Veröffentlicht: (2025)

Prevalence and Predictors of Symptoms of Anxiety or Depression at Diagnosis in Patients With Inflammatory Bowel Disease: An Inception Cohort
von: Christy Riggott, et al.
Veröffentlicht: (2025)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
von: Mary Yue Wang, et al.
Veröffentlicht: (2025)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
von: Lucie Simonis, et al.
Veröffentlicht: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
von: Mary Yue Wang, et al.
Veröffentlicht: (2026)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
von: Yu Shi, et al.
Veröffentlicht: (2025)

Outcome After Surgery for Colon Cancer in a National Cohort of Patients With and Without Inflammatory Bowel Disease
von: Erik Lundqvist, et al.
Veröffentlicht: (2025)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
von: Eduardo Vilar‐Gomez, et al.
Veröffentlicht: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
von: Sai Kiran Kuchana, et al.
Veröffentlicht: (2026)

Systematic Review: Imaging‐Based Morphological Criteria for Liver Cirrhosis—A Call to Standardise
von: Mei Chin Lim, et al.
Veröffentlicht: (2026)

Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation
von: Lucie Simonis, et al.
Veröffentlicht: (2025)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
von: Yee Hui Yeo, et al.
Veröffentlicht: (2026)

Letter: Pharmacotherapy for Alcohol Dependence in Cirrhosis—By Addressing One Issue Do We Create Another?
von: Andrew W. Nguyen, et al.
Veröffentlicht: (2026)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis
von: Stephanie Tsai, et al.
Veröffentlicht: (2025)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue?
von: Louise J. M. Alferink, et al.
Veröffentlicht: (2024)

Letter: Statins for Cirrhosis: Are We Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management?
von: Abdulrahman Ismaiel
Veröffentlicht: (2026)